Scleroderma renal crisis as an initial presentation of systemic sclerosis: A case report and review of the literature

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 171-174

  Logee, Kristin M ^a   Lakshminarayanan, Santhanam ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Literature review; Renal crisis; Systemic sclerosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; LISINOPRIL; METHYLPREDNISOLONE; NITRIC ACID DERIVATIVE; PREDNISONE; PROSTACYCLIN; VALSARTAN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; TETRAZOLE DERIVATIVE; VALINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE DURATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; MIDDLE AGED; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SCLERODERMA; SCLERODERMA RENAL CRISIS; SJOEGREN SYNDROME; SYMPTOM; SYSTEMIC SCLEROSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULITIS; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANEMIA, HEMOLYTIC; COMPLICATION; DELAYED DIAGNOSIS; DRUG COMBINATION; HYPERTENSION, MALIGNANT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; SCLERODERMA, SYSTEMIC; TIME; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANEMIA, HEMOLYTIC; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DELAYED DIAGNOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; SCLERODERMA, SYSTEMIC; TETRAZOLES; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 84946203698     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. LAZAROS IS: New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005; 38: 113-6.
2. MOORE HC, SHEEHAN HL: The kidney of scleroderma. Lancet 1952; 1: 68-70.
3. STEEN VD, CONSTANTINO JP, SHAPIRO AP, MEDSGER TA: Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme inhibitors. Ann Intern Med 1990; 113: 352-7.
4. MAYES MD, LACEY JV, BEEBE-DIMMER J et al.: Prevalence, incidence, survival, and disease characteristic of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-55.
5. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 2007; 100: 485-94.
6. HELFRICH DJ, BANNER B, STEEN VD, MEDSGER TA: Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32: 1128-34.
7. MONTANELLI G, BERETTA A, SANTANIELLO R, SCORZA R: Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S135-9.
8. DeMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
9. STEEN VD, MEDSGER TA, OSIAL TA, ZIEGLER GL, SHAPIRO AP, RODNAN GP: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-86.
10. STEEN VD, MEDSGER TA: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.
11. STEEN VD, MEDSGER TA: Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-3.
12. BATAL I, DOMSIC RT, MEDSGER TA, BAS-TACKY S: Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010; 2010: 543704.
13. BATAL I, DOMSIC RT, SHAFER A et al.: Renal biopsy findings predicting outcome in scleroderma renal crisis. Human Pathology 2009; 40: 332-40.
14. TROSTLE DC, BEDETTI CD, STEEN VD, AL-SABBAGH MR, ZEE B, MEDSGER TA: Renal vascular histology and morphometry in systemic sclerosis: a case-control autopsy study. Arthritis Rheum 1988; 31: 393-400.
15. DENTON CP, LAPADULA G, MOUTHON L, MULLER-LADNER U: Renal complications and scleroderma renal crisis. Rheumatology 2009; 48: iii32-iii35.
16. SHAPIRO CB, LERNER NE, ACKAD AS, ABRAMSON RG, STEIN RM: Malignant hypertension and uremia in scleroderma: efficacy of nephrectomy and hemodialysis. Clin Nephrol 1977; 8: 321-3.
17. MOUTON L, MEHRENBERGER M, TEIXEIRA L et al.: Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011; 42: 95-102.
18. PENN H, QUILLINAN N, KHAN K et al.: Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. Q J Med 2013; 106: 839-48.
19. TEIXEIRA L, MOUTHON L, MAHR A et al.: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-6.
20. GUILLEVIN L, BEREZNE A, SEROR R et al.: Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 2012; 51: 460-7.
21. TRANG G, STEELE R, BARON M, HUDSON M: Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012; 32: 645-53.
22. IUDICI M, van der GOES MC, VALENTINI G, BIJLSMA JWJ: Glucocorticoids in systemic sclerosis: weighing up the benefits and risks - a systematic review. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S157-S165.
23. PENN H, DENTON CP: Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008; 20: 692-6.
24. MOUTHON L, BEREZNE A, BUSSONE G, NOEL LH, VILLIGER PM, GUILLEVIN L: Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clinic Rev Allergy Immunol 2011; 40: 84-91.
25. GONZALEZ EA, SCHMULBACH E, BASTANI B: Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis. Am J Kidney Dis 1994; 23: 317-9.
26. MOLINA JF, ANAYA JM, CABRERA GE, HOFFMAN E, ESPINOZA LR: Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 1995; 22: 557-60.
27. ARAD U, BALBIR-GURMAN A, DOENYAS-BARAK K, AMIT-VAZINA M, CASPI D, ELKAYAM O: Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 2011; 41: 223-9.
28. OMAIR MA, MOHAMED N, JOHNSON SR, AHMAD Z, LEE P: ANCA-associated vasculitis in systemic sclerosis report of 3 cases. Rheumatol Int 2013; 33: 139-43.
29. QUEMENEUR T, MOUTHON L, CACOUB P et al.: Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine 2013; 92: 1-9.
30. OKANO Y, STEEN VD, MEDSGER TA: Auto-antibody reactive with RNA Polymerase III in systemic sclerosis. Ann Intern Med 1993; 119: 1005-13.
31. NIKPOUR M, HISSARIA P, BYRON J et al.: Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from and Australian cohort. Arthritis Res Ther 2011; 13: R211.
32. HESSELSTRAND R, SCHEJA A, WUTTGE DM: Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012; 41: 39-43.
33. NGUYEN B, SHERVIS A, ARNETT FC, MAYES MD: Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37: 1068-9.
34. AGGARWAL R, LUCAS M, FERTIG N, ODDIS CV, MEDSGER TA: Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60: 1112-8.
35. FISHER ER, RODNAN GP: Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol 1958; 65: 29-39.
36. DENTON CP, BLACK CM: Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18: 271-90.
37. CASKEY FJ, THACKER EJ, JOHNSTON PA, BARNES JN: Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997; 349: 620.
38. WALKER K, POPE J: Treatment of systemic sclerosis complications: what to use when first-line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
39. DHAUN N, MacINTYRE IM, BELLAMY C, KLUTH DC: Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis 2009; 54: 726-31.
40. IZZEDINE H, ROUVIER P, DERAY G: Endothelin receptor antagonism-based treatment for scleroderma renal crisis. Am J Kidney Dis 2013; 62: 394-5.
41. BLEYER AJ, DONALDSON LA, MCINTOSH M, ADAMS PL: Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001; 37: 1152-61.